RVO
HomeMarketplace
Register
Register
Register

ServiceUpdated on 24 July 2025

Qualification & Validation Services

daniel lüscher

CEO at QBDC GmbH

Nusshof, Switzerland

About

QBDC's Qualification & Validation consulting services are crucial for biopharmaceutical companies aiming to ensure their facilities, equipment, utilities, and processes consistently meet regulatory requirements and deliver intended results. They provide the expertise to establish and maintain a validated state throughout the entire lifecycle of a biopharmaceutical product.

Key aspects of QBDC's Qualification & Validation consulting include:

  • Comprehensive Documentation Creation: QBDC assists in the development of all necessary qualification and validation documentation, including:

    • Validation Master Plans (VMPs)

    • User Requirement Specifications (URS)

    • Functional Specifications (FS)

    • Design Qualifications (DQ)

    • Installation Qualifications (IQ)

    • Operational Qualifications (OQ)

    • Performance Qualifications (PQ)

    • Process Validation Protocols and Reports

    • Cleaning Validation Protocols and Reports

    • Computer System Validation (CSV) documentation

  • Risk-Based Approach: QBDC implements a risk-based approach to qualification and validation, focusing resources on areas of highest risk to product quality and patient safety. This ensures efficiency while maintaining robust compliance.

  • GMP Upgrades and Remediation: They guide companies through necessary GMP upgrades and remediation activities to bring existing facilities, systems, or processes into current regulatory compliance. This includes identifying gaps, developing action plans, and overseeing implementation.

  • Equipment and Utility Qualification: QBDC specializes in qualifying critical equipment (e.g., bioreactors, chromatography systems) and utilities (e.g., purified water systems, HVAC) to ensure they operate as intended and consistently produce quality results.

  • Process Validation: They design and execute process validation studies to confirm that manufacturing processes consistently yield products meeting predefined quality attributes. This involves defining critical process parameters and demonstrating control.

  • Computer System Validation (CSV): With increasing reliance on digital systems, QBDC provides expertise in validating computer systems used in GxP environments, ensuring data integrity, security, and compliance with regulations like FDA 21 CFR Part 11.

  • Audit Readiness and Support: QBDC helps prepare companies for regulatory inspections and provides support during audits, ensuring all validation documentation and practices can withstand scrutiny.

  • Ensuring Accuracy and Efficiency: The ultimate goal of QBDC's Qualification & Validation services is to guarantee accuracy, efficiency, and full regulatory compliance in all validation activities, thereby minimizing risks and accelerating product development timelines.

Type

  • Consulting
  • Manufacturing

Applies to

  • Development stages and support fuctions - Development and (GMP) manufacturing
  • Development stages and support fuctions - Data management and analytics

Organisation

QBDC GmbH

Consultant

4453 Nusshof, Switzerland

Similar opportunities

  • Service

    CMC Consulting

    • Consulting
    • Development
    • Innovative therapies - Gene therapy
    • Innovative therapies - Stem cell therapy
    • Innovative therapies - Oncolytic viruses
    • Innovative therapies - Immune cell therapy
    • Innovative therapies - Somatic cell therapy
    • Development stages and support fuctions - Data management and analytics
    • Development stages and support fuctions - Contract research (CRO / CRMO)
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Development and (GMP) manufacturing
    • Development stages and support fuctions - Pre-clinical research and development
    • Development stages and support fuctions - Commercial strategy and market access

    daniel lüscher

    CEO at QBDC GmbH

    Nusshof, Switzerland

  • Product

    EDDI - Epigenetic Digital Data Interface

    • Innovative therapies - RNA therapy
    • Innovative therapies - Gene therapy
    • Innovative therapies - Gene editing
    • Innovative therapies - Nanomedicine
    • Innovative therapies - Stem cell therapy
    • Innovative therapies - Oncolytic viruses
    • Innovative therapies - Microbiome therapy
    • Innovative therapies - Precision medicine
    • Innovative therapies - Immune cell therapy
    • Innovative therapies - Somatic cell therapy
    • Innovative therapies - Tissue engineered products
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - Organ-on-Chip
    • Innovative human-based test models - In silico human models
    • Development stages and support fuctions - Regulatory and compliance
    • Innovative human-based test models - Bioprinted tissues and constructs
    • Development stages and support fuctions - Data management and analytics
    • Innovative human-based test models - Assembloids and multi-tissue models
    • Development stages and support fuctions - Contract research (CRO / CRMO)
    • Innovative human-based test models - 2D & 3D in vitro cell culture models
    • Development stages and support fuctions - Early discovery / basic research
    • Development stages and support fuctions - Funding, capital and investments
    • Development stages and support fuctions - Ethics and social responsibility
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Development and (GMP) manufacturing
    • Development stages and support fuctions - Technology development and validation
    • Development stages and support fuctions - Pre-clinical research and development
    • Development stages and support fuctions - Commercial strategy and market access

    daniel lüscher

    CEO at QBDC GmbH

    Nusshof, Switzerland

  • Service

    Oncolines cancer cell panel profiling

    • Consulting
    • Development
    • Innovative therapies - Precision medicine
    • Innovative therapies - Immune cell therapy
    • Innovative human-based test models - 3D spheroids
    • Innovative human-based test models - 2D & 3D in vitro cell culture models
    • Development stages and support fuctions - Clinical research and development
    • Development stages and support fuctions - Pre-clinical research and development

    Guido Zaman

    Managing Director at Oncolines B.V.

    Oss, Netherlands